article thumbnail

STAT+: Lawmakers ask FDA to review Hims’ Super Bowl ad for ‘misleading’ patients

STAT

wrote that they worry that the Hims ad, which will be seen by millions of people during the big game on Sunday, “risks misleading patients by omitting any safety or side effect information” about the compounded weight loss drugs that it promotes. Dick Durbin (D-Ill.) and Roger Marshall (R-Kan.)

article thumbnail

STAT+: Pharmalittle: We’re reading about a China probe of AstraZeneca, a ‘troubling’ Super Bowl ad, and more

STAT

Food and Drug Administration to “take action” against a “dangerous” ad that Hims & Hers plans to run during the Super Bowl promoting the use of compounded versions of GLP-1 drugs for combating obesity. “The commercial is misleading in its entirety,” the industry group wrote to the agency.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

STAT+: Pharmalittle: We’re reading about HHS reducing public comment, a Lilly obesity drug ad, and more

STAT

The ad, asking patients to “be a healthy skeptic,” was released soon after a commercial from telehealth firm Hims & Hers, selling a compounded weight loss drug, premiered at the Super Bowl. Continue to STAT+ to read the full story…

article thumbnail

Covid-19 surveillance added new burdens on essential workers — and gave them little data to protect their health

STAT

They also didn’t offer workers clear and accurate information that would help them protect their health, according to a new report by the nonprofit Data & Society.

article thumbnail

US FDA flags dosing risks from compounded versions of Novo’s weight-loss drug

Express Pharma

Food and Drug Administration recently warned patients and doctors about dosing errors associated with compounded versions of Novo Nordisk’s weight-loss and diabetes drugs. It urged healthcare providers and compounders to provide the appropriate syringe size and counsel patients on how to measure the dose,” informed the statement.

article thumbnail

The discovery of a new and compounding cybersecurity threat to pharmacies

pharmaphorum

Criminals gained access to user login information (credentials) somewhere online. Because many people use the same login information for several websites, the criminals began to test those credentials on other sites and subsequently use them on vulnerable online pharmacies.

article thumbnail

STAT+: Pharmalittle: We’re reading about FDA oversight of shortages, AstraZeneca threats, and more

STAT

By law, that should have prohibited compounding pharmacies from making copies of the drug, as they are allowed to do so only when the treatment is on the shortage list. However, some traditional retail pharmacies said supplies of Lilly’s treatment were still unavailable, and a trade group representing compounders took the FDA to court.